hrp0084p3-891 | Fat | ESPE2015

Bone Age Assessment and Glucose Metabolism in Overweight and Obese Children

Paul Corina , Mogoi Mirela , Velea Iulian

Background: Bone age (BA) tends to exceed chronological age (CA) in obese children. There are studies showing that insulin may directly influence skeletal growth. Objective: To determine whether there is an association between BA and glucose metabolism in a group of overweight and obese children.Methods: The study included 55 obese or overweight children, mean age: 11.56±3.07 years old. Anthropometric indexes (weight, height, BMI, waist circumferenc...

hrp0084p3-968 | GH & IGF | ESPE2015

Bone Age Maturation in Prader-Willi Syndrome on GH Treatment is Accelerated in Pre-Pubertal Age without Affecting Final Height

Eiholzer Urs , Obwegeser Carla , Witassek Fabienne , Meinhardt Udo

Background: In children with Prader-Willi Syndrome (PWS) on Growth Hormone treatment (GHT) bone age (BA) acceleration is often observed. Little is known on reasons and consequences.Objective and hypotheses: To quantify BA acceleration in pre-pubertal PWS children on GHT and to investigate how BA correlates with weight gain and age at onset of GHT. To assess how final height depends on pre-pubertal bone maturation, weight gain and age at onset of GHT....

hrp0095p1-412 | Adrenals and HPA Axis | ESPE2022

A single centre experience of aromatase inhibitors to limit bone age advancement in pre-pubertal boys with adrenal disorders causing androgen excess

Shaunak Meera , Zichichi Giulia , Peters Catherine , Brain Caroline , Dattani Mehul

Introduction: Anastrozole, an aromatase inhibitor, prevents the conversion of androgen to oestrogen, which is required for the adolescent growth spurt and the attainment of peak bone mass. Anastrozole may help minimise bone age (BA) advancement in conditions associated with adrenal androgen excess, such as congenital adrenal hyperplasia (CAH) and premature adrenarche.Objectives: 1. To describe baseline characteristics an...

hrp0092p2-240 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Bone Age Determination in Girls with Early Puberty and Limitations of Adult Height Prediction: Can Automated Evaluation (BoneXpert™)be a Solution?

Yesiltepe-Mutlu Gul , Capaci Merve , Uzunkopru Gizem , Hatun Sükrü

Introduction: One of the factors affecting the treatment decision in early puberty is bone age (BA) evaluation and adult height prediction (AHP), accordingly. These calculations have certain limitations. In this study, we aimed to compare the AHP results calculated by Bayley-Pinneau (BP) and Roche-Wainer-Thissen(RWT) methods based on BA evaluation by using Greulich-Pyle(GP) atlas and BoneXpert™ software.Methods: A t...

hrp0092p2-218 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

The Difference of Body Mass Index (BMI) Score Before and After Gonadotropin-Releasing Hormone Agonist (GnRHa) Treatment in Central Precocious Puberty Girls

Choi Yujung , Lee Seonhwa , Kim Seulki , Ahn Moonbae , Kim Shinhee , Cho Wonkyoung , Cho Kyoungsoon , Jung Minho , Suh Byungkyu

Purpose: We investigated the difference of body mass index (BMI) score before and after gonadotropin-releasing hormone agonist (GnRHa) treatment in central precocious puberty girls (CPP).Methods: Medical records of 188 girls with CPP treated with GnRHa were reviewed. All patients completed the therapy. The patients were categorized into two groups according to initial BMI; normal weight group (BMI < 85 percentile) an...

hrp0089rfc11.6 | Bone, Growth Plate &amp; Mineral Metabolism 2 | ESPE2018

Reference Values of Automated Bone Age and Bone Health Index for Mexican Children and Adolescents

Lora America Liliana Miranda , Espindola Montserrat Espinosa , Gonzalez Desiree Lopez , Loyo Mariana Sanchez-Curiel , Suarez Pilar Dies , Klunder Miguel Klunder

Background: BoneXpert is a software for automated measurement of bone age (BA) and radiogrammetry (bone health index). The precision error of the software for BA measure is smaller than the human rating error and the accuracy relative to the human routine ratings is 0.80 years. Differences in skeletal maturation between ethnicities have been reported, so it is important to have specific references for the own population.Objective: To present the automate...

hrp0086p2-p51 | Adrenal P2 | ESPE2016

Bone Health Index in Children and Adolescents with Congenital Adrenal Hyperplasia

Alsaffar Hussain , Davies Rosie , Reed John , Das Urmi , Senniappan Senthil , Didi Mohammed , Blair Jo

Introduction: Patients with congenital adrenal hyperplasia (CAH) require life long glucocorticoid (GC) therapy. In CAH, the adverse effect of GC on bone health (BH) may be counteracted by the effect of modest elevations in adrenal androgens.Aim: To examine relationships between BH index (BHI) SDS, calculated by BoneXpert on bone age (BA) x-rays, BA, hydrocortisone (HC) dose (mg/m2 per day), and mean 17-hydroxyprogesterone (17-OHP) concentratio...

hrp0082p3-d1-933 | Puberty and Neuroendocrinology | ESPE2014

Effect on BMI of GnRH Analogue Treatment in Central Precocious Puberty or Early and Fast Puberty Girls

Qiuli Chen , Zhe Su , Yanhong Li , Huamei Ma , Hongshan Chen , Jun Zhang , Minlian Du

Objective: We assessed in a retrospective unicenter study the effect on BMI of treatment with GnRH analogs (GnRHa) in central precocious puberty (CPP) or early and fast puberty (EFP) girls.Methods: The BMI of 318 girls (227 CPP and 91 EFP) who treated with GnRHa alone were analyzed. Among them 89 were followed up to their final adult hight (FAH).Results: Before GnRHa treatment started, the girls with CPP and EFP had a mean BMI SDS ...

hrp0095rfc11.4 | Late Breaking | ESPE2022

Are GnRH agonists beneficial in final adult height after 8 years old? Data from a Portuguese National Digital Platform of idiopathic Central Precocious Puberty

Espada Filipa , Castro Carolina , Luisa Leite Ana , Galo Elisa , Antunes Ana , Castro Sofia , Robalo Brigida , Amaral Daniela , Ferreira Sofia , Limbert Catarina

Objective: Central precocious puberty (CPP) is a common condition in pediatric endocrinology practice. Gonadotropin-releasing hormone agonists (GnRHa) treatment is safe, but the real effect on final height and the ideal timing for treatment remains controversial. The purpose of the authors was to evaluate a nationwide representative group of CPP Portuguese girls treated with GnRHa, assess the effectiveness of treatment and the growth outcome before and after 8...

hrp0092rfc2.3 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Growth Hormone Effects on Metacarpal Bone Geometry and Bone Age in Growth Hormone-Deficient Children

Martin David D , Ranke Michael B , Henrik Thodberg Hans , Binder Gerhard

Purpose: To track the effects of growth hormone on bone geometry and maturation in children with isolated growth hormone deficiency (GHD).Methods: 299 left hand X-rays from 77 short prepubertal children (54 boys and 23 girls) with isolated GHD were analysed for changes in metacarpal thickness, width, length, medullary diameter, the Bone Health Index (BHI) and bone age (BA) from one year preceding until four years after s...